Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 01, 2015 07:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune and Universal Cells Announce Collaboration to Develop Allogeneic T-Cell Therapies

PHILADELPHIA and OXFORD, United Kingdom, Dec. 01, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, and...
November 24, 2015 11:15 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Initiates Phase I / II Trial Evaluating Its Affinity Enhanced T-Cell Therapy Targeting NY-ESO-1 in Patients With the Most Common Type of Lung Cancer

OXFORD, United Kingdom and PHILADELPHIA, Nov. 24, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of engineered T-cell therapy to treat cancer, today...
November 13, 2015 07:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Reports First Quarter Financial Results for Fiscal Year 2015-16

PHILADELPHIA and OXFORD, United Kingdom, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of T-cell therapy to treat cancer, today reported...
November 12, 2015 10:16 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Participate in the Jefferies Autumn 2015 Global Healthcare Conference

PHILADELPHIA and OXFORD, United Kingdom, Nov. 12, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of T-cell therapy to treat cancer, today announced that...
November 05, 2015 08:15 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Data From Clinical Study of NY-ESO Affinity Enhanced T-Cell Therapy in Synovial Sarcoma at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)

PHILADELPHIA and OXFORD, UK, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today presents...
October 30, 2015 09:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer (SITC)

PHILADELPHIA and OXFORD, United Kingdom, Oct. 30, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of T-cell...
October 16, 2015 10:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Participate in the 2015 BIO Investor Forum

PHILADELPHIA and OXFORD, United Kingdom, Oct. 16, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), (“Adaptimmune” or the “Company”), a clinical stage biopharmaceutical company...
October 13, 2015 06:00 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Reports Full Fiscal Year 2015 Financial Results

PHILADELPHIA and OXFORD, United Kingdom, Oct. 13, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), (“Adaptimmune” or the “Company”), a clinical stage biopharmaceutical company...
October 09, 2015 08:30 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune Growth Leads to Long-Term Expansion Plans in Philadelphia

PHILADELPHIA and OXFORD, UK, Oct. 09, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc. (Nasdaq:ADAP), (“Adaptimmune” or the “Company”), a clinical stage biopharmaceutical company focused on...
October 07, 2015 09:13 ET | Source: Adaptimmune Therapeutics plc

Adaptimmune to Report Full Fiscal Year 2015 Financial Results on October 13, 2015

PHILADELPHIA, Pa. and OXFORD, UK, Oct. 07, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), (“Adaptimmune” or the “Company”), a clinical stage biopharmaceutical company focused...